Aggressive lipid-lowering therapy beneficial after bypass grafting, say researchers.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D002792:Cholestyramine Resin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008148:Lovastatin / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D000960:Hypolipidemic Agents; D002792:Cholestyramine Resin; D014859:Warfarin; D008148:Lovastatin